Discover PHAXIAM

Our ambition: to become a world leader in phage therapy and address the critical medical need caused by antimicrobial resistance.

Learn more
icon

OUR MISSION

PHAXIAM relies on the use of phages to fight resistant bacterial infections

Learn more
icon

OUR HISTORY

PHAXIAM is the result of the merger, in June 2023, of two French biotech companies: ERYTECH and PHERECYDES.

Learn more
icon

OUR COMBINATION

A combination that capitalizes on the complementary expertise and resources of two companies.

Learn more
icon

OUR TEAM

A committed and experienced team to achieve the full potential of phage therapy.

Learn more
fond illu

Our solutions

Phage therapy is now coming at the forefront of the fight against resistant bacterial infections,
recognised as a major public health issue in human health.

Learn more

PHAGE THERAPY

PHAXIAM develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics.

 

The phages (or bacteriophages) are harmless to human organisms and specifically eradicate bacteria in an ultra-targeted way to fight microbial infections. They offer excellent efficacy against bacteria – including bacteria that are multi-resistant to antibiotics –, are very well tolerated due to their high specificity and adapt very quickly to bacterial mutations while respecting microbiota, unlike antibiotics.

Learn more

ANTIMICROBIALRESISTANCE (AMR)

Antibiotic resistance is a major global public health problem, responsible today for over 1 million deaths a year worldwide, and which could, according to the World Health Organization, cause 10 million deaths a year by 2050 if nothing is done.

 

The growing threat of antibiotic resistance has been the main driver of the focus on developing alternative treatments, including bacteriophages.

 

 

 

Learn more

Our
last news

Read our press releases, events and news

All news
  • Press release
    PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

    Read more
  • News
    PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

    As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million).

    Read more
  • Press release
    PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

    Conference call and webcast (English) on Wednesday, November 15, 2023at 8:30am ET / 2:30pm CET

    Read more
  • News
    PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

    Read more
  • Press release
    PHAXIAM announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps has initiated coverage of its shares

    TP ICAP Midcap began covering the stock with a “Buy” recommendation and valued the Company at €8.5 per share

    Read more

Contact
our team

Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.

Contact us